Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 22, 2007

Primary Completion Date

December 31, 2017

Study Completion Date

December 7, 2017

Conditions
Fibrous Dysplasia of Bone
Interventions
DRUG

risedronate

During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.

DRUG

placebo

placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.

DRUG

risedronate

During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.

DRUG

placebo

placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.

Trial Locations (8)

1200

Cliniques Universitaires Saint Luc, Brussels

2300

Leids Universitair Medisch Centrum, Leiden

12200

Hospital Benjamin Franklin, Berlin

50924

Cologne Clinical Centre, Cologne

69120

Heildeberg Clinical Centre, Heidelberg

69437

Hopital E Herriot, Lyon

75475

Hopital Lariboisiere, Paris

75679

Hopital Cochin, Paris

All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER

collaborator

Charite University, Berlin, Germany

OTHER

lead

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

NCT00445575 - Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone | Biotech Hunter | Biotech Hunter